Skip to content Skip to menu

Government commits to PBS, time to unpack the detail

Tuesday, 8 May 2018

Media Release

MA welcomes the announcement of $1.4 billion for the listing of innovative medicines on the PBS, as announced in today’s 2018/19 Federal Budget. This will help ensure all Australians have access to new and innovative medicines they need when they need them.

We are encouraged by the $1 billion future listing provision and the Government’s commitment to list all new medicines recommended by the PBAC.  We look forward to further discussion on this, and on the revised payment administration systems for high cost medicines.

We know that with new highly targeted medicines coming in through the pipeline, continued investment in the PBS is needed.

The Government has acknowledged the budget is in good shape, now it’s time to see some investment in high value areas such as the PBS and the innovative medicines industry.

A strong PBS not only helps patients, it also supports thousands of medical researchers and jobs and the research-based medicines and health sectors, and encourages investment in medical research in Australia.

Medicines Australia is pleased with the Government’s commitment to research and development within the innovative pharmaceutical sector with the exemption of clinical trials under changes to the R&D Tax Incentive and no intensity threshold.

The Government has also responded to industry’s Pre-Budget submission by budgeting to boost the profile of Australia’s innovative medicines industry internationally through the National Health and Medical Industry Growth Plan.

Medicines Australia notes the new PBS listings announced in the Budget that will provide further important health benefits for patients. This includes Refractory multiple myeloma, relapsing remitting MS, PreP, relapsed of refractory Hodgkin’s lymphoma; $42.5 million over five years 2017-18 for Maternal Pertussis, High dose 65 years plus flu, 12 Month meningococcal ACWY.

There are still unanswered questions arising from the Budget, which we will be working through over the coming days.

Medicines Australia remains committed to working constructively with the Government to deliver a solution that will enable the Government to invest in the PBS so that new innovative medicines can continue to be listed for Australians.

CONTACT:

Natalie Wimmer –Communications Manager – 0450 728 660 – nwimmer@medaus.com

Information

As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at medicinesaustralia.com.au/covid-19/

Top